Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Wedbush Recommends Buying Sangamo BioSciences (SGMO) on Weakness
August 6, 2015 1:07 PM EDTWedbush analyst Liana Moussatos is out defending Sangamo BioSciences (NASDAQ: SGMO) mid-day with shares getting sliced to the tune of 16% following Q2 results that missed the Street. The analyst notes the $218 million cash on hand is enough to cover significant clinical progress and they recommend buying the stock on weakness.
"We anticipate significant clinical progress in the next 6- 18 months," Moussatos... More
